Halda Therapeutics
Abigail Hundt's work experience begins with their role as a Biology Intern at Halda Therapeutics from January 2021 to June 2021. Halda Therapeutics is a biotechnology platform company focused on discovering medicines through innovative molecule creation. Abigail then joined CheminPharma LLC as an Intern from August 2020 to January 2021. CheminPharma LLC specializes in providing services related to drug discovery processes. Prior to that, Abigail worked as a Barista at Starbucks from June 2016 to June 2020. Abigail'smost recent role is as an Associate Scientist at Halda Therapeutics, starting in June 2021 and still ongoing. Additionally, they worked as a Student Researcher at the University of New Haven from December 2019 to April 2020, where they focused on researching DNA repair genes and their relation to cancer development post infection with Lyme disease-causing bacteria. In this role, they utilized various techniques such as cell culture, infection procedures, q-RTPCR, and western blotting. Abigail also got the opportunity to present their research project during a student Symposium.
Abigail Hundt attended the University of New Haven from 2016 to 2020, where they obtained a Bachelor's degree in Molecular Genetics. In January 2020, they also received certification in Chemical Hygiene and Hazard Communication Training from the same institution.
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.